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Introduction
Under physiological conditions, serum calcium 
concentration is tightly regulated. Abnormalities of 
parathyroid function, bone resorption, renal calcium 
reabsorption or dihydroxylation of vitamin D may cause 
regulatory mechanisms to fail and serum calcium to rise. 
Serum calcium is bound to albumin, and measurements 
should be adjusted for serum albumin. This guideline 
aims to take the non-specialist through the initial phase 
of assessment and management.
Severity of hypercalcaemia
 • Shortened QT interval and dysrhythmias
 • Nephrolithiasis, nephrocalcinosis
 • Pancreatitis
 • Peptic ulceration
 • Hypertension, cardiomyopathy
 • Muscle weakness
 • Band keratopathy
Causes
<3.0 mmol/L: often asymptomatic and does not 
usually require urgent correction
3.0–3.5 mmol/L: may be well tolerated if it has 
risen slowly, but may be symptomatic and prompt 
treatment is usually indicated
>3.5 mmol/L: requires urgent correction due to the 
risk of dysrhythmia and coma
Clinical features of hypercalcaemia
 • Polyuria and thirst
 • Anorexia, nausea and constipation
 • Mood disturbance, cognitive dysfunction, confusion 
and coma
 • Renal impairment
Ninety percent of hypercalcaemia is due to primary 
hyperparathyroidism or malignancy
Less common causes include
 • Thiazide diuretics
 • Familial hypocalciuric hypercalcaemia
 • Non-malignant granulomatous disease
 • Thyrotoxicosis
 • Tertiary hyperparathyroidism
 • Hypervitaminosis D
 • Rhabdomyolysis
 • Lithium
 • Immobilisation
 • Adrenal insufficiency
 • Milk-alkali syndrome
 • Hypervitaminosis A
 • Theophylline toxicity
 • Phaeochromocytoma
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Investigation
History
 – Symptoms of hypercalcaemia and duration
 – Symptoms of underlying causes, e.g. weight loss, night 
sweats, cough
 – Family history
 – Drugs including supplements and over-the-counter 
preparations
Examination
 – Assess for cognitive impairment
 – Fluid balance status
 – For underlying causes, including neck, respiratory, 
abdomen, breasts, lymph nodes
ECG
 – Look for shortened QT interval or other conduction 
abnormalities
Bloods
 – Calcium adjusted for albumin
 – Phosphate
 – PTH
 – Urea and electrolytes
High calcium and high PTH = primary or tertiary 
hyperparathyroidism*
High calcium and low PTH = malignancy or other less 
common causes
(*Familial hypocalciuric hypercalcaemia may be 
misdiagnosed as primary hyperparathyroidism due to 
hypercalcaemia with inappropriately normal or raised PTH. 
However, the hypercalcaemia is not usually severe and it is 
less likely to present as an emergency)
If further treatment required after intravenous  
saline, consider intravenous bisphosphonates
Management
Rehydration
Intravenous 0.9% saline 4–6 L in 24 h
 – Monitor for fluid overload if renal impairment 
or elderly
 – Loop diuretics rarely used and only if fluid overload 
develops; not effective for reducing serum calcium
 – May need to consider dialysis if severe renal failure
Zoledronic acid 4 mg over 15 min
OR  Pamidronate 30–90 mg (depending on severity of 
hypercalcaemia) at 20 mg/h
OR Ibandronic acid 2–4 mg
 – Give more slowly and consider dose reduction in renal 
impairment
 – Monitor serum calcium response: will reach nadir at 
2–4 days
 – Can cause hypocalcaemia if vitamin D deficiency or 
suppressed PTH
Second-line treatments
Glucocorticoids (inhibit 1,25OHD production)
 – In lymphoma, other granulomatous diseases or 25OHD 
poisoning
 – Prednisolone 40 mg daily
 – Usually effective in 2–4 days
Calcimimetics, denosumab, calcitonin
 – Under specialist supervision
 – Can be considered if poor response to other  
measures
Parathyroidectomy
 – Can be considered in acute presentation of primary 
hyperparathyroidism if severe hypercalcaemia and 
poor response to other measures
Disclaimer
The document should be considered as a guideline only; it is not intended 
to determine an absolute standard of medical care. The doctors concerned 
must make the management plan for an individual patient.
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